Ratio Therapeutics secures $70M Series C for radiopharma trials as Vogenx eyes $67M IPO

Ratio Therapeutics, a Boston-based biotech, announced a $70 million Series C financing to fund its radiopharmaceutical development program.

The round was led by existing backers Duquesne Family Office and Bristol Myers Squibb, with participation from new investors.

The capital will be used to advance clinical trials of its radiopharma candidates.

In a separate announcement, Vogenx disclosed plans to pursue a $67 million initial public offering.

Both moves reflect ongoing investor interest in specialty biotech and imaging sectors.